"Anti-Par2 Antibodies And Uses Thereof" in Patent Application Approval Process (USPTO 20230242639).
In: Drug Week, 2023-08-25, S. 2748-2748
serialPeriodical
Zugriff:
The antibody or antigen-binding fragment thereof of claim 2, wherein the VH comprises an amino acid sequence that is at least 80%, 85%, 90%, 92%, 93%, 95%, 97%, 99% or 100% identical to SEQ ID NO: 12 and wherein the VL comprises an amino acid sequence that is at least 80%, 85%, 90%, 92%, 93%, 95%, 97%, 99% or 100% identical to SEQ ID NO: 17. The antibody or antigen-binding fragment thereof of claim 2, wherein the VH comprises an amino acid sequence corresponding to SEQ ID NO: 831 and wherein the VL comprises an amino acid sequence corresponding to SEQ ID NO: 7 or 17. The antibody or antigen-binding fragment of claim 2, wherein the antibody or antigen-binding fragment prevents trypsin, tryptase and/or matriptase from interacting with PAR2. The antibody or antigen-binding fragment of claim 2, wherein the antibody or antigen-binding fragment binds to PAR2 with greater affinity at a pH of 7.4 than at a pH of 6.0. [Extracted from the article]
Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
"Anti-Par2 Antibodies And Uses Thereof" in Patent Application Approval Process (USPTO 20230242639).
|
---|---|
Zeitschrift: | Drug Week, 2023-08-25, S. 2748-2748 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6440 (print) |
Schlagwort: |
|
Sonstiges: |
|